Senior health service figures raise concerns that roll out of new Alzheimer's drugs could cost taxpayer £1 billion per year and endanger the lives of patients with the disease

Two much-hyped Alzheimer's drugs may never get NHS approval after an official report claimed they have 'limited clinical benefit'.

Source: the Mail online | Health - February 11, 2024 Category: Consumer Health News Source Type: news